I'm interested in finding out if there are data available regarding mutations affecting 53BP1 that are known - or supposed to - cause resistance to PARPi in the contest of breast or ovarian cancer. So far, most of the data I've found, did not really show specific mutations ( or the domains affected ) but rather the only showed the loss of 53BP1 expression. I would be interested in knowing where those mutations were occurring and how they were compromizing 53BP1 function so that HR could be restore.